Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTAM: TAA-Specific CTLs in Active Myeloma
NCT02291848Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2015
- Primary completion
- Dec 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAA-CTL in multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) (3 arms), sponsored by Baylor College of Medicine. Primary endpoint: Number of Patients with Adverse Events at 8 weeks. Started Apr 2015; status: active, not recruiting.
02
Drugs
TAA-CTL
03
Conditions
multiple myeloma (MM)monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02291848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291848.